Vault compositions for immunization

Patent metadata

Field	Value
Publication number	US-9463232-B2
Application number	US-201514864186-A
Country	US
Kind code	B2
Filing date	Sep 24, 2015
Priority date	May 15, 2008
Publication date	Oct 11, 2016
Grant date	Oct 11, 2016

Abstract

Methods and compositions are provided herein for immunizing a subject by administering to the subject an effective amount of an immunogenic peptide or an immunogenic fragment or variant thereof incorporated within a vault-like particle carrier. The methods and compositions advantageously exhibit enhanced ability to induce cell-mediated immunity and/or antibody-based immunity.

First claim

What is claimed is:

1. A method for stimulating a cellular immune response in a subject, comprising administering to the subject an effective amount of an antigenic peptide or an antigenic fragment or variant thereof incorporated within a vault complex, thereby stimulating a cellular immune response.

2. The method of claim 1 , wherein the antigenic peptide is fused to INT.

3. The method of claim 1 , wherein the antigenic peptide is fused to MVP.

4. The method of claim 3 , wherein the antigenic peptide is fused to the N-terminus of MVP.

5. The method of claim 1 , wherein the vault complex comprises MVP.

6. The method of claim 5 , wherein the number of MVP is 1-78.

7. The method of claim 5 , wherein the number of MVP is 78.

8. The method of claim 5 , wherein the vault complex further comprises VPARP or modified VPARP, or a portion of VPARP, or a modified portion of VPARP.

9. The method of claim 1 , wherein the cellular immune response is induction of Th cells.

10. The method of claim 9 , wherein the Th cells comprise Th-1 cells.

11. The method of claim 1 , wherein the cellular immune response is induction of CD4 + and/or CD8 + T-cells.

12. The method of claim 1 , wherein the cellular immune response is production of INF γ.

13. The method of claim 1 , wherein the vault-like particle further comprises a targeting moiety.

14. The method of claim 13 , wherein the targeting moiety is on the surface of the vault-like particle.

15. The method of claim 13 , wherein the targeting moiety comprises an Fc binding domain.

16. The method of claim 1 , wherein the effective amount of the antigenic peptide or the antigenic fragment or variant thereof incorporated within the vault complex is administered in the form of a pharmaceutical composition, which further comprises at least one pharmaceutically acceptable excipient.

17. The method of claim 16 , wherein the excipient is an adjuvant.

18. The method of claim 16 , wherein the composition does not include an adjuvant.

Assignees

• Univ California

Inventors

• Kickhoefer Valerie A
• Rome Leonard H
• Kelly Kathleen A
• Champion Cheryl

Classifications

• A61K2039/57

  characterised by the type of response, e.g. Th1, Th2 · CPC title

• A61K39/118 Primary

  Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci · CPC title

• A61K2039/6031

  Proteins · CPC title

• A61K39/385

  Haptens or antigens, bound to carriers · CPC title

• A61P31/04

  Antibacterial agents · CPC title